{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:55:36Z","timestamp":1747176936035,"version":"3.40.5"},"reference-count":117,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.1080\/03007995.2024.2354533","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T13:19:26Z","timestamp":1715347166000},"page":"935-945","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials"],"prefix":"10.1080","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-3186","authenticated-orcid":false,"given":"Vanda P.","family":"Peixoto","sequence":"first","affiliation":[{"name":"Chemical and Biomolecular Sciences, School of Health, Polytechnic Institute of Porto, Porto, Portugal"},{"name":"Center for Translational Health and Medical Biotechnology Research (TBIO)\/Health Research Network (RISE-HEALTH), Polytechnic of Porto, School of Health, Porto, Portugal"}]},{"given":"Cristina","family":"Prud\u00eancio","sequence":"additional","affiliation":[{"name":"Chemical and Biomolecular Sciences, School of Health, Polytechnic Institute of Porto, Porto, Portugal"},{"name":"Center for Translational Health and Medical Biotechnology Research (TBIO)\/Health Research Network (RISE-HEALTH), Polytechnic of Porto, School of Health, Porto, Portugal"},{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal"}]},{"given":"M\u00f3nica","family":"Vieira","sequence":"additional","affiliation":[{"name":"Chemical and Biomolecular Sciences, School of Health, Polytechnic Institute of Porto, Porto, Portugal"},{"name":"Center for Translational Health and Medical Biotechnology Research (TBIO)\/Health Research Network (RISE-HEALTH), Polytechnic of Porto, School of Health, Porto, Portugal"},{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-522128"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095646"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.05.014"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01157"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2201664"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0086"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094136"},{"key":"e_1_3_5_10_1","unstructured":"SHEPHERD: safety in hemolytic PNH patients treated with eculizumab: a multi-center open-label research design [Internet]. Clinicaltrials.gov. U.S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT00130000"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0748-9"},{"key":"e_1_3_5_12_1","unstructured":"Phase II clinical study of eculizumab (h5G1.1-mAb) in hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2024. https:\/\/clinicaltrials.gov\/study\/NCT01192399."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1404-y"},{"key":"e_1_3_5_14_1","unstructured":"Phase II clinical study of eculizumab (h5G1.1-mAb) in hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) patients: extension Study to C07-001 Protocol [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT01194804."},{"key":"e_1_3_5_15_1","unstructured":"Open label extension study of eculizumab in patients with transfusion dependent PNH [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT00122317."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25068"},{"key":"e_1_3_5_17_1","unstructured":"An open-label multi-center study of eculizumab in children and adolescents with a diagnosis of paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT00867932."},{"key":"e_1_3_5_18_1","unstructured":"Open-label multicenter study to assess the efficacy safety pharmacokinetics pharmacodynamics and immunogenicity of eculizumab in complement inhibitor treatment na\u00efve adult participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) in China [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05886244."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01068-2"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719874728"},{"key":"e_1_3_5_22_1","unstructured":"An open-label intrapatient dose-escalation study to evaluate the safety tolerability efficacy pharmacokinetics and pharmacodynamics of ALXN1210 administered intravenously to patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT02598583."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020644"},{"key":"e_1_3_5_24_1","unstructured":"Phase A open-label 2 multiple ascending dose study to evaluate the efficacy safety tolerability immunogenicity pharmacokinetics and pharmacodynamics of ALXN1210 administered intravenously to patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT02605993."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966137"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236877"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02016-8"},{"key":"e_1_3_5_30_1","unstructured":"A Phase 3 Randomized Open-Label Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03056040."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1725468"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237497"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02339-3"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281562"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13411"},{"key":"e_1_3_5_36_1","unstructured":"Randomized A. Double-blind active-controlled phase 3 study evaluating the efficacy and safety of ABP 959 compared with eculizumab in adult subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03818607."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166722"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115004"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00591-9"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112262"},{"key":"e_1_3_5_41_1","unstructured":"An open-label single arm study to evaluate the efficacy and safety of REGN3918 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement inhibitor-naive or have not recently received complement inhibitor therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03946748."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146178"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01955-9"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00940-9"},{"key":"e_1_3_5_45_1","unstructured":"A phase 1\/2 single-ascending and multiple-ascending dose safety tolerability pharmacokinetics and pharmacodynamics study of subcutaneously administered ALN-CC5 in healthy adult volunteers and patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT02352493."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.748"},{"key":"e_1_3_5_47_1","unstructured":"A randomized open-label two-arm study to evaluate the safety efficacy and pharmacodynamic effects of pozelimab and cemdisiran combination treatment in patients with paroxysmal nocturnal hemoglobinuria who have received pozelimab monotherapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04811716."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163236"},{"key":"e_1_3_5_49_1","unstructured":"Single arm A open-label study to assess the safety efficacy and pharmacodynamic effects of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04888507"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970092.68730.83"},{"key":"e_1_3_5_51_1","unstructured":"A randomized open-label C5 inhibitor-controlled study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria who are complement inhibitor treatment-naive or have not recently received complement inhibitor therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05133531."},{"key":"e_1_3_5_52_1","unstructured":"An open-label extension study to evaluate the long-term safety tolerability and efficacy of pozelimab and cemdisiran combination therapy in patients with Paroxysmal Nocturnal Hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05744921."},{"key":"e_1_3_5_53_1","unstructured":"An adaptive phase I\/II study to assess safety efficacy pharmacokinetics and pharmacodynamics of crovalimab in healthy volunteers and patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03157635."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003399"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18274"},{"key":"e_1_3_5_56_1","unstructured":"A phase III multicenter single arm study evaluating the efficacy safety pharmacokinetics and pharmacodynamics of crovalimab in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04654468."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26998"},{"key":"e_1_3_5_58_1","unstructured":"A phase III randomized open-label active-controlled multicenter study evaluating the safety pharmacokinetics pharmacodynamic and efficacy of crovalimab versus eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04432584"},{"key":"e_1_3_5_59_1","unstructured":"A phase III randomized open-label active-controlled multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with complement inhibitors. [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04434092."},{"key":"e_1_3_5_60_1","unstructured":"An open-label proof of concept study to assess the efficacy safety and pharmacokinetics of LFG316 an anti-C5 monoclonal antibody in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT02534909."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.265868"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-020-02921-5"},{"key":"e_1_3_5_63_1","unstructured":"A phase 2 multicenter open-label uncontrolled study to evaluate the safety tolerability efficacy pharmacokinetics and pharmacodynamics of RA101495 in subjects with paroxysmal nocturnal hemoglobinuria who have an inadequate response to eculizumab [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03030183."},{"key":"e_1_3_5_64_1","unstructured":"Phase 2 multicenter open-label uncontrolled study to evaluate the safety tolerability efficacy pharmacokinetics and pharmacodynamics of RA101495 in subjects with Paroxysmal Nocturnal Hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03078582."},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281780"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16305"},{"key":"e_1_3_5_67_1","unstructured":"Investigational product; coversin. phase III safety and efficacy in three-part two-arm randomised open label evaluation in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03588026."},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2109462"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01560-8"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04903-x"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25960"},{"key":"e_1_3_5_72_1","unstructured":"A phase 3 randomized multicenter open-label controlled study to evaluate the efficacy and safety of pegcetacoplan in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U.S.National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04085601."},{"key":"e_1_3_5_73_1","first-page":"e92","volume-title":"Lancet Haematol. 2022","volume":"9","author":"del Pozo Mart\u00edn Y.","year":"2021","unstructured":"del Pozo Mart\u00edn Y. 2021 ASH annual meeting Lancet Haematol. 2022;9:p. e92\u2013e93."},{"key":"e_1_3_5_74_1","unstructured":"A phase III randomized multi-center open-label active-comparator controlled study to evaluate the efficacy and safety of APL-2 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03500549."},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00210-1"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04887-8"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1971182"},{"key":"e_1_3_5_79_1","unstructured":"An open label non-randomized multi-center extension study to evaluate the long-term safety and efficacy of pegcetacoplan in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03531255."},{"key":"e_1_3_5_80_1","unstructured":"An open label single-arm phase 2 study to evaluate the safety pharmacokinetics and biologic activity of pegcetacoplan in pediatric patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04901936."},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13137"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153312"},{"key":"e_1_3_5_83_1","unstructured":"A phase 2 open-label proof of concept study to assess the efficacy safety and pharmacokinetics of ACH-0144471 in untreated patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03053102."},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261826"},{"key":"e_1_3_5_85_1","unstructured":"An open-label study to evaluate efficacy and safety of long-term treatment with ACH-0144471 in participants who completed clinical study ACH471-100 [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03181633."},{"key":"e_1_3_5_86_1","unstructured":"A phase 2 open-label study of ACH-0144471 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who have an inadequate response to eculizumab monotherapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03472885."},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124748"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011388"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134388"},{"key":"e_1_3_5_90_1","unstructured":"A phase 3 study of danicopan (ALXN2040) as add-on therapy to a C5 inhibitor (Eculizumab or Ravulizumab) in patients with paroxysmal nocturnal hemoglobinuria who have clinically Evident Extravascular Hemolysis (EVH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04469465."},{"key":"e_1_3_5_91_1","unstructured":"A Long-term Extension (LTE) study to characterize the safety and efficacy of danicopan as an add-on therapy to a complement component 5 inhibitor (C5i) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously treated with danicopan in an alexion-sponsored clinical study [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05389449."},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00315-0"},{"key":"e_1_3_5_93_1","unstructured":"A phase 2 open-label proof of concept study to assess the efficacy safety and pharmacokinetics of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients as monotherapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04170023."},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169301"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846188.51290.75"},{"key":"e_1_3_5_96_1","unstructured":"An open-label multicenter intra-subject dose escalation study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and therapeutic potential of BCX10013 in subjects with Paroxysmal Nocturnal Hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT06100900."},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01870"},{"key":"e_1_3_5_99_1","unstructured":"An open label single arm multiple dose study to assess efficacy safety pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to standard of care (soc) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with signs of active hemolysis [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03439839."},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00028-4"},{"key":"e_1_3_5_101_1","unstructured":"A multi-center randomized open-label efficacy safety pharmacokinetics and pharmacodynamics study assessing multiple LNP023 doses in adult patients with paroxysmal nocturnal hemoglobinuria and active hemolysis [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03896152."},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022006960"},{"key":"e_1_3_5_103_1","unstructured":"A randomized multicenter active-comparator controlled open-label trial to evaluate efficacy and safety of oral twice daily LNP023 in adult patients with PNH and residual anemia despite treatment with an intravenous anti-C5 antibody. [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04558918."},{"key":"e_1_3_5_104_1","unstructured":"A multicenter single-arm open-label trial to evaluate efficacy and safety of oral twice daily iptacopan in adult PNH patients who are naive to complement inhibitor therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04820530."},{"key":"e_1_3_5_105_1","unstructured":"An open label multicenter Roll-over Extension Program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed pnh phase 2 and phase3 studies with iptacopan [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT04747613."},{"key":"e_1_3_5_106_1","unstructured":"A multicenter single arm open-label trial to evaluate efficacy and safety of oral twice daily iptacopan in adult PNH patients who have Hb \u2265 10\u2009g\/dL in response to anti-C5 antibody and switch to iptacopan [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05630001."},{"key":"e_1_3_5_107_1","unstructured":"A phase II open-label study of NM8074 in Soliris\u00ae-treated patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05646563."},{"key":"e_1_3_5_108_1","unstructured":"A phase II open-label study of NM8074 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05646524."},{"key":"e_1_3_5_109_1","unstructured":"A phase II open label multi dose study of NM8074 in soliris-treated subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05731050."},{"key":"e_1_3_5_110_1","unstructured":"A phase 1 randomized placebo-controlled double blind single ascending dose study in healthy volunteers followed by open label treatment in patients with pnh to evaluate the safety tolerability PK and PD of ADX-038 [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05876312."},{"key":"e_1_3_5_111_1","unstructured":"A multi-center randomized open-label phase 2 study to evaluate the efficacy and safety of MY008211A tablets in adult patients with paroxysmal nocturnal hemoglobinuria and active hemolysis. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT06050226."},{"key":"e_1_3_5_112_1","unstructured":"A multi-center randomized parallel open-label clinical phase II study to evaluate the efficacy and safety of MY008211A in adult Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with signs of active hemolysis [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT06134414."},{"key":"e_1_3_5_113_1","unstructured":"An multicenter randomized open-label proof of concept study to assess the efficacy safety of HRS-5965 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT06051357."},{"key":"e_1_3_5_114_1","unstructured":"A Phase 1b proof of concept study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and preliminary efficacy of OMS906 in patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05889299."},{"key":"e_1_3_5_115_1","unstructured":"A Phase 1b proof of concept study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and preliminary efficacy of OMS906 in PNH patients with a sub-optimal response to the C5 inhibitor ravulizumab [Internet]. Clinicaltrials.gov. U.S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05972967."},{"key":"e_1_3_5_116_1","unstructured":"An Open-label phase 2 study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and efficacy of kp104 in complement inhibitor-na\u00efve subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT05476887."},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159172"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209692"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2024.2354533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:07:55Z","timestamp":1727190475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2024.2354533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":117,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,2]]}},"alternative-id":["10.1080\/03007995.2024.2354533"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2024.2354533","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}